Comparative Bioavailability of Sildenafil 50‐mg Film‐Coated Tablets and 50‐mg Orally Disintegrating Films in Healthy Mexican Subjects: Results From a Randomized, Open‐Label, Crossover Study-Reference-Cited by-同舟云学术

Comparative Bioavailability of Sildenafil 50‐mg Film‐Coated Tablets and 50‐mg Orally Disintegrating Films in Healthy Mexican Subjects: Results From a Randomized, Open‐Label, Crossover Study

Published:2018-06-27 Issue:3 Volume:8 Page:404-410
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Aguirre Luis García¹,Olmedo Isabel Ruiz¹,Nolasco Araceli Medina¹,Romo Yamanqui Ibáñez¹,Reyes Liz Medina¹,Hernández Dolores Adriana Aguilera²,Vargas Ana Laura Rojas²

Affiliation:

1. Investigación Farmacológica y Biofarmacéutica (IFaB) Tlalpan, México DF Mexico

2. Comercializadora y Distribuidora en General Jazih, Mexico City, SA de CV Mexico

Funder

Comercializadora y Distribuidora en General Jazih SA de CV

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.599

Reference6 articles.

1. A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction

2. A randomised bioequivalence study on vigrex in twelve healthy human subjects under fasting conditions;Penumajji S;J Pharm Res,2009

3. Clinically significant drug interactions;Ament PW;Am Fam Physician,2000

4. Pharmacokinetic drug interactions of phosphodiesterase‐5 inhibitors mediated by cytochrome P450 3A4 isoform;Pentyala S;Int J Med Med Sci,2011

5. Relative Bioavailability of Chewable and Conventional Film-Coated Tablet Formulations of Sildenafil 100 mg in Healthy Volunteers Under Fasting Conditions

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of the Orally Disintegrating Strip Sildenafil for the Treatment of Erectile Dysfunction: A Prospective, Randomized Trial;Sexual Medicine;2021-12

2. The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue;Andrology;2019-07-26